Blood cancer therapy reverses incurable leukaemia in some patients

A therapy once considered the stuff of science fiction has reversed aggressive and incurable blood cancers in some patients, doctors say.

The treatment involves precisely editing the DNA in white blood cells to turn it into a “living drug” that fights cancer.

The first girl to receive treatment The person whose story we tell in 2022He is still recovering from the disease and now plans to become a cancer scientist.

Eight more children and two adults with T-cell acute lymphoblastic leukemia have now been treated; Almost two-thirds (64%) of patients were in remission.

T cells are thought to be the body’s guardians, seeking out and destroying threats, but in this form of leukemia they grow out of control.

Chemotherapy and bone marrow transplants failed for trial participants. The only option left, other than experimental medicine, was to make their deaths more comfortable.

“I literally thought I was going to die and not grow up and do the things every child deserves to do,” says Alyssa Tapley, 16, from Leicester.

He was the first person in the world to be treated at Great Ormond Street Hospital and is now enjoying life.

The revolutionary treatment three years ago involved deleting the old immune system and creating a new one. He spent four months in the hospital and was unable to see his brother in case he contracted an infection.

But his cancer is now undiagnosed and he only needs annual checkups. Alyssa is taking her A-levels, the Duke of Edinburgh’s Award, taking driving lessons and planning her future.

“I’m considering an apprenticeship in biomedical science and hopefully one day I’ll get into blood cancer research too,” he said.

The team at University College London (UCL) and Great Ormond Street Hospital used a technology called base editing.

Bases are the language of life. Four types of bases (adenine (A), cytosine (C), guanine (G) and thymine (T)) are the building blocks of our genetic code. Just as the letters of the alphabet form words with meaning, the billions of bases in our DNA constitute the user manual of our body.

Base editing allows scientists to zoom in on a specific section of the genetic code and then transform it from one type to another by changing the molecular structure of just one base, rewriting the instruction manual.

Researchers wanted to harness the natural power of healthy T cells to find and destroy threats and use it against T-cell acute lymphoblastic leukemia.

This is a difficult feat. They had to engineer good T cells to hunt down the bad cells before the treatment destroyed itself.

They started with healthy T cells from a donor and began modifying them.

The first key edit disabled the targeting mechanism of the T cells so that they could not attack the patient’s body.

Second, it removed a chemical marker called CD7 that is found on all T cells. It is important to remove this to prevent the therapy from self-destructing.

The third arrangement was an “invisibility cloak” that prevented cells from being killed by the chemotherapy drug.

The final stage of genetic modification instructed T cells to hunt for anything with the CD7 marker on it.

Now the modified T cells would destroy any other T cells they found, whether cancerous or healthy, but they would not attack each other.

Patients are injected with the therapy, and if their cancer remains undetected after four weeks, they receive a bone marrow transplant to rebuild their immune system.

“A few years ago this would have been science fiction,” says Prof Waseem Qasim from UCL and Great Ormond Street.

“We basically need to disrupt the entire immune system.

“This is a deep and intense treatment, it requires a lot of effort on the part of the patients, but when it works, it works very well.”

The study, published in the New England Journal of Medicine, reports the results of the first 11 patients treated at Great Ormond Street and King’s College Hospital. It shows that nine people achieved a profound recovery that enabled them to undergo bone marrow transplants.

Seven people remain disease-free for three months to three years after treatment.

One of the biggest risks of treatment is infections in which the immune system is destroyed.

In two cases, the cancer lost its CD7 signatures, causing it to hide from treatment and reappear in the body.

Dr. from the bone marrow transplant department at Great Ormond Street Hospital. “Given how aggressive this particular form of leukemia is, these are quite striking clinical results, and frankly, I am very happy that we have managed to offer hope to patients who would otherwise have lost their leukemia,” said Robert Chiesa.

King’s consultant haematologist Dr. “We’ve seen impressive responses to clearing leukemia from seemingly incurable conditions; it’s a very powerful approach,” said Deborah Yallop.

Commenting on the research, Dr said, senior medical officer at UK stem cell charity Anthony Nolan. Tania Dexter said: “Given that these patients had a low chance of survival before the trial, these results give hope that such treatments will continue to progress and can be applied to more patients.”